TP53 and lung cancer: These effects are due to a downregulationof CDK1, CDK2, Cyclin A2, and Cyclin B2 and the inhibition of thephosphorylation of p53.63 In cell linesassociated with lung cancer, it is the aglycone that has the greatestbiological potential, focused on the direct or indirect regulationof p53, resuming apoptosis pathways in azasteroidal compounds.